CLINICAL TRIALS
CENTRE
The Clinical Trials Centre of the 4th Oncology Clinic supports our patients’ participation in clinical trials, that is, in organised research protocols that evaluate new treatments or new combinations of treatments, under strict rules of safety and scientific monitoring.
What a clinical trial is
A research protocol that tests whether a new treatment is safe and more effective than the established one. Every trial is approved by the National Organization for Medicines and the National Ethics Committee before it starts.
What is guaranteed for you
- Detailed information and written consent before every step
- The right to withdraw at any time, with no effect on your care
- Closer monitoring by the research team
- Access to treatments before they become available in Greece
How to take part
How to take part in a clinical trial
- Information
Your doctor explains what the trial is, what it offers and what it involves, and answers every question.
- Consent
You take part only if you choose to, with written consent, and you can withdraw at any time.
- Eligibility screening
Tests that confirm the trial suits your particular case.
- Treatment and follow-up
Close monitoring by the clinical trials coordinator and the medical team.
Studies we take part in
The studies of the 4th Oncology Clinic registered in the international ClinicalTrials.gov registry, with Dr Helena Linardou as principal investigator or site investigator. The list is refreshed from the registry.
Source ClinicalTrials.gov and PubMed, updated 9 September 2026. 21 registered studies, 8 open for participation, and 34 publications reporting clinical-trial results with Dr Linardou among the authors. Titles are given as registered. Each link opens the registry record or the publication.
Ongoing studies (9)
Completed and earlier studies (12)
Clinical and Molecular Study With Digital Support of Patients With Inoperable Lung Cancer
Checkpoint Inhibitors in Patients With Cancer and Underlying Autoimmune Disease
Immunotherapy in Combination With Chemotherapy in Small-cell Lung Cancer
Published clinical-trial results (34)
- 2026Comprehensive molecular profiling of advanced NSCLC in Greek patients:A prospective HeCOG study
- 2026SNF-CLIMEDIN: A Randomized Trial of Digital Support and Intervention in Patients With Advanced Non-Small Cell Lung Cancer. A Hellenic Cooperative Oncology Group Study
- 2025Intercalated Avelumab plus platinum-based chemotherapy in patients with Extensive-Stage Small-Cell Lung cancer (PAVE): Final outcome, immunophenotypic and biomarker analysis of a multi-center phase II Hellenic Cooperative Oncology Group study
- 2025Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial
- 2025LEAP-008: Lenvatinib Plus Pembrolizumab for Metastatic NSCLC That Has Progressed After an Anti-Programmed Cell Death Protein 1 or Anti-Programmed Cell Death Ligand 1 Plus Platinum Chemotherapy
- 2024Implementing geriatric assessment for dose optimization of CDK4/6 inhibitors in older breast cancer patients
- 2024Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation
- 2023Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1
- 2023Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial
- 2023First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817
- 2022First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial
- 2022Real-world safety and efficacy data of immunotherapy in patients with cancer and autoimmune disease: the experience of the Hellenic Cooperative Oncology Group
- 2021An Observational Study to Assess the Molecular Epidemiology and Direct Medical Costs of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients with Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer Treated with Afatinib in Real-World Clinical Settings in Greece
- 2021First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1
- 2020Real-world clinical outcome and toxicity data and economic aspects in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy: the experience of the Hellenic Cooperative Oncology Group
- 2020Impact of Bevacizumab Versus Erlotinib on Tumor Metrics in Patients With Previously Untreated Advanced Non-small Cell Lung Cancer: A Study by the Hellenic Cooperative Oncology Group
- 2019Genotyping KRAS and EGFR Mutations in Greek Patients With Non-small-cell Lung Cancer: Incidence, Significance and Implications for Treatment
- 2018Gemcitabine Combined with the mTOR Inhibitor Temsirolimus in Patients with Locally Advanced or Metastatic Pancreatic Cancer. A Hellenic Cooperative Oncology Group Phase I/II Study
- 2018Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- 2015Prognostic Significance of VEGFC and VEGFR1 mRNA Expression According to HER2 Status in Breast Cancer: A Study of Primary Tumors from Patients with High-risk Early Breast Cancer Participating in a Randomized Hellenic Cooperative Oncology Group Trial
- 2014The androgen receptor as a surrogate marker for molecular apocrine breast cancer subtyping
- 2012The prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of high-risk early breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial
- 2010Irinotecan/fluorouracil/leucovorin or the same regimen followed by oxaliplatin/fluorouracil/leucovorin in metastatic colorectal cancer
- 2010A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study
- 2008Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: a phase II Study of the Hellenic Cooperative Oncology Group with biomarker evaluation
- 2008Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00
- 2006The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. A Phase II study of the Hellenic Cooperative Oncology Group
- 2005Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group
- 2005Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study
- 2004Combination of pegylated liposomal doxorubicin (PLD) and paclitaxel in patients with advanced soft tissue sarcoma: a phase II study of the Hellenic Cooperative Oncology Group
- 2004Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group
- 2004The effect of temozolomide-based chemotherapy in patients with cerebral metastases from melanoma
- 2000Phase II study of pegylated liposomal doxorubicin: inactive in recurrent small-cell lung cancer. A Hellenic Cooperative Oncology Group Study
- 1996Carboplatin alone compared with its combination with epirubicin and cyclophosphamide in untreated advanced epithelial ovarian cancer: a Hellenic co-operative oncology group study
The Centre’s team
The Clinic’s Director, Dr Helena Linardou, is an active member of research groups with a strong presence in clinical and translational research, such as the Hellenic Cooperative Oncology Group (HeCOG), securing access to large international collaborative trials and to new, pioneering anticancer treatments.
Is there a trial for my case
Speak to your treating physician or contact us. The team checks whether any of the active trials suits your disease, its stage and the treatment you have received, and informs you in detail about the benefits and the limitations. The team’s research work is recorded in the Clinic’s publications.